Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Postpartum depression is common in mothers early after childbirth and produces harmful effects not only on mothers, but also on infants and young children. Parturients with prenatal depression are at increased risk of postpartum depression. Low-dose s-ketamine can be used for antidepressant therapy. We hypothesize that low-dose s-ketamine has a therapeutic effect on parturients with prenatal depression. This study is designed to investigate whether low-dose s-ketamine administered after childbirth can reduce the incidence of postpartum depression in parturients with prenatal depression.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Treatments: Esketamine; Ketamine

Criteria

Inclusion Criteria:

• Parturients with age ≥18 years;

• Presence of prenatal depression (EPDS score ≥10);

• Provide written informed consents.

Exclusion Criteria:

• History of psychiatric disease (schizophrenia) or communication barriers that prevent normal communication before childbirth;

• Severe complications during pregnancy (such as severe preeclampsia, placenta accreta, or HELLP [Hemolysis, Elevated Liver enzymes and Low Platelets] syndrome);

• ASA physical status classification ≥III;

• Presence of contraindications to ketamine, including refractory hypertension, severe cardiovascular disease (heart function classification ≥III), or hyperthyroidism;

• Refuse to participate.